Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Mellinghoff
    Mellinghoff
  4. Shuman
    Shuman
  5. Rosenblum
    Rosenblum
  6. Dunkel
    Dunkel
  7. Karajannis
    Karajannis
  8. Saltz
    Saltz
  9. Souweidane
    Souweidane
  10. Panageas
    Panageas

Groups

  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)
  7. Department of Pathology and Laboratory Medicine (415)
  8. Gastrointestinal Oncology Service (386)
  9. Genitourinary Oncology Service (367)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2131)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (92)
  5. Editorial (84)
  6. Guidelines (36)
  7. Correspondence (26)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (10)
Groups
  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Stewart Shuman (88)
  6. Marc Rosenblum (87)

More People

Years
  1. 2025 (129)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1670)
  2. Neuro-Oncology (855)
  3. JNCI: Journal of the National Cancer Institute (492)
  4. Nucleic Acids Research (210)
  5. Clinical Infectious Diseases (140)
  6. American Journal of Clinical Pathology (106)

More Publications

Results (4676)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Assessment of the Bethesda System for Reporting Thyroid Cytopathology: Surgical and long-term clinical follow-up of 2,893 thyroid fine-needle aspirations
    Journal Article

    Sauter, J. L.; Lehrke, H.; Zhang, X.; Al Badri, O. T.; Rodriguez-Gutierrez, R.; Delivanis, D. A.; Singh Ospina, N.; Donegan, D.; Hamidi, O.; Iñiguez-Ariza, N.; more...
    American Journal of Clinical Pathology (2019)

    Fulltext@MSK | Save
  • Phase 3 multicenter, open-label, randomized study of infigratinib versus gemcitabine plus cisplatin in the first-line treatment of patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF trial
    Meeting Abstract

    Javle, M.; Borbath, I.; Clarke, S.; Hitre, E.; Louvet, C.; Macarulla, T.; Oh, D.; Spratlin, J.; Valle, J.; Weiss, K.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • A phase II trial of tepotinib in patients with non-small cell lung cancer (NSCLC) harboring MET alterations: The VISION study
    Meeting Abstract

    Paik, P.; Cortot, A.; Felip, E.; Sakai, H.; Mazieres, J.; Horn, L.; Griesinger, F.; Bruns, R.; Scheele, J.; Straub, J.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • ANCHOR CRC: A phase 2, open-label, single arm, multicenter study of encorafenib (ENCO), binimetinib (BIM), plus cetuximab (CETUX) in patients with previously untreated BRAF V600E-mutant metastatic colorectal cancer (mCRC)
    Meeting Abstract

    Grothey, A.; Yaeger, R.; Paez, D.; Tabernero, J.; Taïeb, J.; Yoshino, T.; Groc, M.; Vedovato, J.; Chetaille, E.; Van Cutsem, E.
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Outcomes based on Albumin-Bilirubin (ALBI) grade in the phase 3 CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellulat carcinoma (HCC)
    Meeting Abstract

    Miksad, R.; Cicin, I.; Chen, Y.; Klumpen, H.; Kim, S.; Lin, Z.; Youkstetter, J.; Sen, S.; Cheng, A.; Meyer, T.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Activity of larotrectinib in TRK fusion lung cancer
    Meeting Abstract

    Drilon, A.; Kummar, S.; Moreno, V.; Patel, J.; Lassen, U.; Rosen, L.; Childs, B. H.; Nanda, S.; Cox, M. C.; Ku, N. C.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • A phase II study of [fam-] trastuzumab deruxtecan (DS-8201a) in HER2-overexpressing or -mutated advanced non-small cell lung cancer
    Meeting Abstract

    Planchard, D.; Li, B. T.; Murakami, H.; Shiga, R.; Lee, C. C.; Wang, K.; Jänne, P. A.
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Crizotinib in advanced ROS1-rearranged non-small cell lung cancer (NSCLC): Overall survival (OS) and updated safety from PROFILE 1001
    Meeting Abstract

    Shaw, A.; Riely, G. J.; Bang, Y. J.; Kim, D. W.; Camidge, D. R.; Shapiro, G. I.; Usari, T.; Wang, S. C.; Wilner, K.; Clark, J. W.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Double PIK3CA mutations in cis enhance PI3Kα oncogene activation and sensitivity to PI3Kα inhibitors in breast cancer
    Meeting Abstract

    Vasan, N.; Razavi, P.; Johnson, J. L.; Shao, H.; Reznik, E.; Smith, M. L.; Sebra, R.; Cantley, L. C.; Scaltriti, M.; Baselga, J.
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Update on the phase II SUMMIT trial: Neratinib + fulvestrant for HER2-mutant, HR-positive, metastatic breast cancer
    Meeting Abstract

    Smyth, L. M.; Saura, C.; Piha-Paul, S. A.; Lu, J.; Mayer, I. A.; Brufksy, A. M.; Spanggaard, I.; Arnedos, M.; Cutler, R. E.; Hyman, D. M.
    Annals of Oncology (2019)

    Fulltext@MSK | Save